Search
Forigerimod
go.drugbank.com/drugs/DB12490InvestigationalForigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.
Categories: Ribonucleoprotein, U1 Small NuclearIcodextrin
go.drugbank.com/drugs/DB00702ApprovedInvestigationalIt is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease.
Categories: Compounds used in a research, industrial, or household settingImlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalThe FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with … [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.
R673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning
MK-8777
go.drugbank.com/drugs/DB18904Investigational(174001/P05704/MK-8777-001)). … MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder
Dolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalDolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative … This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Ferric oxide
go.drugbank.com/drugs/DB11576ApprovedInvestigationalIt is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite. … Iron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3.
Categories: Compounds used in a research, industrial, or household settingFlunisolide
go.drugbank.com/drugs/DB00180ApprovedIt is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Categories: Corticosteroids for Systemic Use, Drugs for Obstructive Airway DiseasesBexotegrast
go.drugbank.com/drugs/DB16515InvestigationalThe compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840).
Categories: Experimental Unapproved Treatments for COVID-19Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] In June 2023, Rozanolixizumab-noli was approved by the FDA under Priority Review for the treatment of adult patients with generalized myasthenia gravis who are positive for the anti-acetylcholine … [A260207] AChR is vital for signal transduction in the neuromuscular junctions (NMJ) by generating muscle end plate potentials to propagate action potential.